CureVac
Biotech · Germany · Founded 2000 · acquired
CureVac (the Tübingen company that pioneered mRNA as a medicine in 2000 and then lost the Covid vaccine race) was bought by BioNTech in an all-stock deal worth about $1.25bn and delisted from Nasdaq on 16 January 2026.
The record
1 figures · 0 rounds · 0 backers · 3 feed items
Every one of them carries its source, its date, and its age when it has one. Reading the record takes a free account; the account is how you keep a watchlist.